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Acrodose versus single donor platelets was 28.9 versus 19.8,
respectively. The median increase for Acrodose versus single
donor was 28 versus 16. The median time to next transfusion
for Acrodose versus single donor was 4 versus 2 days. In
subgroup analysis, the average increase among bonemarrow
transplant patients receiving Acrodose versus single donor
platelets was 21.7 versus 27.8, respectively. The median
increase for Acrodose versus single donor was 18 versus 20.
The median time to next transfusion for Acrodose versus
single donor was the same at 3 days. Among acute leukemia
patients, the average increase in patients receiving Acrodose
versus single donor platelets was 28 versus 18.6, respectively.
Themedian increase for Acrodose versus single donor was 27
versus 15. The median time to next transfusion for Acrodose
versus single donor was 4 versus 2 days.
Conclusion: In our single institutional experience, Acodose
platelets induced a more robust response and increased the
time to next transfusion compared to single donor platelets
among all patients and especially acute leukemia patients,
however this was not seen with the bone marrow transplant
patients. The reason for this is unclear andmore studies need
to be done.341
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Background: Human rhinovirus (HRV) is well known to
cause upper or lower respiratory tract infection (URTI/LRTI)
and is associated with increased morbidity and mortality in
immunocompromised adults such as those with cancer or
those undergoing hematopoietic stem cell transplantation
(HSCT). Asymptomatic children who are about to undergo
HSCT with a positive respiratory viral panel (RVP) pose a
special challenge and create a dilemma for providers when
deciding whether to move forward with HSCT in patients
with active viral disease.
Methods: We retrospectively reviewed the medical records
of all children who underwent HSCT from Jan 1, 2006 eMay
1, 2014 who had a RVP by PCR performed as part of the
pretransplant workup or within 180 days following HSCT.
Patients with rhinovirus identiﬁed pretransplant were not
treated with IVIG but received routine prophylaxis with IVIG.
Patients who developed rhinoviral infection were treated
with high dose IVIG. We reviewed data of all patients to
evaluate its impact on overall outcome. Demographic,
clinical, microbiologic, management, and outcome data were
collected.
Results: 50 pediatric HSCT patients were identiﬁed. A total of
23 patients were asymptomatic and identiﬁed on pretrans-
plant DFA screening. None of these patients developed
complications related to rhinovirus during the transplant. 21
patients were identiﬁed after HSCT was started due to
workup for fever or respiratory symptoms. None of these
children appeared to have signiﬁcant morbidity and
mortality related to rhinoviral infection. Of note,11/11 (100%)
umbilical cord recipients continued to have positive RVP and
viral shedding for several months following HSCT.Conclusions: Rhinovirus does not appear to have a negative
impact on the course of children undergoing HSCT.
The presence of rhinovirus is not a contraindication to
proceeding to transplant in children. Umbilical cord blood
transplant patients appeared to have delayed clearance of
the virus but this did not impact their clinical outcome.342
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Purpose: The objective of this studywas to compare the time
to engraftment of autologous hematopoietic stem cell
transplant (HSCT) patients who received ﬁlgrastim on day +5
versus day +10. In addition, number of febrile days, antibiotic
use, documented infection, and length of hospitalization
were compared. We hypothesized that duration of neu-
tropenia and incidence of neutropenic fever would be similar
in patients who received ﬁlgrastim on day +5 versus day +10.
Methods: Prior to initiation, the study received approval
from the Institutional Review Board. A HSCT database was
used to identify patients who have received autologous HSCT
from January 1, 2007 to June 30, 2013. Patients were included
if they received ﬁlgrastim on day +5 + 1 or day +10 + 1 post
HSCT. Patients werematched based on age + 5 years and type
of malignancy. The health-system’s electronicmedical record
system, HSCT database, and medication charts were used to
collect the following data: age, gender, weight, height, type
of malignancy requiring transplant, date of autologous
HSCT, chemotherapy conditioning regimen, ﬁlgrastim and
antibiotic administration, documented infections, length of
stay, and survival.
Results: There were 79-matched pairs that met inclusion
criteria. The day +5 group had an average time to engraft-
ment of 8.27 days compared to 8.96 days in the day +10
group (p¼0.006). All secondary endpoints were similar
between both groups, including rates of infection and total
febrile days. There was no difference seen with average
length of stay between the two groups (p¼0.745).
Conclusion: The average time to engraftment was
statistically signiﬁcant, in favor of patients who received
ﬁlgrastim earlier in their transplant course on day +5.
However the primary and secondary endpoints results are
not clinically signiﬁcant. Future directions include a cost
analysis to assess economic outcomes.343
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